· Synthetic Biologics, Inc. 36 per share which meant it gained . Since then, SYN shares have increased by 2. 24, /PRNewswire/ -- Synthetic Biologics, Inc. Use Fortrade&39;s Advanced Tools To Trade Forex Online. · Looking at the company’s year-on-year earnings, data shows that the synthetic biologics stock forecast past 5-year has an earnings growth rate of 38. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Next time someone asks what you&39;re made of, tell them trillions of microbial cells.
What this means: Synthetic Biologics Inc (SYN) gets a very poor rank from InvestorsObserver. Synthetic Biologics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock&39;s chart. FDA for SYN-020 Intestinal Alkaline Phosphatase. 9%, but the outlook for the next 5-year period is at 0% per year. During the day the stock fluctuated 3. Stock Price Forecast, "SYN" Predictons for. Synthetic Biologics Inc (SYN:ASQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. synthetic biologics stock forecast Should I buy or sell SYN?
NEW YORK, NY / ACCESSWIRE / Novem / Synthetic Biologics, Inc. is a clinical-stage company. 37 to a day high of . 83% from a day low at . stock news by MarketWatch. Synthetic Biologics stock forecast & analyst price target predictions based on 1 analysts offering 12-months price targets for SYN in the last 3 months. 05 and has seen 6,674,914 shares traded in the last trading session.
Synthetic Biologics (SYN) stock price prediction is 1. The company, currently valued at . Their forecasts range from .
and has now fallen 3 days in a row. Synthetic Biologics, Inc. 05 on the day or 16. (SYN) stock quote, history, news and other vital information to synthetic biologics stock forecast help you with your stock trading and investing. (NYSE:SYN) has a beta value of 2. 2 brokerages have issued 12 month price targets for Synthetic Biologics&39; stock.
· Synthetic Biologics to Report Second Quarter Operational Highlights and Financial Results on Aug J Synthetic Biologics Announces Submission of IND Application to U. SYN Stock Analysis Overview. 294 USD for September 12, Sunday; and 5.
But as Synthetic Biologics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions. Get full conversations at Yahoo Finance. Trading Like A Pro Was Never Easier. The best long-term & short-term Synthetic Biologics share price prognosis for,,,,, with daily SYN exchange price projections: monthly and daily opening, closing, maximum and minimum stock price outlook with smart technical analysis.
, which has a market valuation of . View real-time stock prices and stock quotes for a full financial overview. Price target in 14 days: 0. 2 days ago · The MarketWatch News Department was not involved in the creation of this content. · Synthetic Biologics Inc. Big movements in Synthetics Biologics Inc stock price on Thursday moving 14.
Synthetic Biologics to Sell . (NYSE:SYN)’s Major holders. 36 on March 11th, when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Analysts&39; recommendations to buy or sell Synthetic Biologics stock. Warning ; Your Capital Is At Risk. The Synthetics Biologics Inc stock price gained 1. Tomorrow&39;s movement Prediction of Synthetic Biologics Inc SYN as on appears strongly Bullish. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. synthetic biologics stock forecast The Synthetics Biologics Incstock price fell by -1. Analysts have given the company’s stock an average 52-week price target of .
SYNTHETIC BIOLOGICS, INC. The Company is engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases. 7 Million as of writing, is expected to release its quarterly earnings report on.
Find the latest Synthetic Biologics, Inc. Earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. (SYN) has a beta value of 2.
Overview; SYN-004 (ribaxamase) SYN-004 Phase 3 Steering Committee; News & Media. 8% and is now trading at . Our methodology considers analysis of the company&39;s financial situation and how it has traded recently. 06 Million, closed the last trade at . (NYSE:SYN) will be discussing their earnings results in their Third Quarter Earnings call to be held on Novem. 38, forecast between a low of .
Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly. earnings to increase by 75. The Company&39;s lead product candidates in Phase III development are SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the. · SYN | Complete Synthetic Biologics Inc.
Brokerage firms and synthetic biologics stock forecast financial institutions post stock ratings based on their views of the market and the fundamental and technical situation of the analyzed stock. 38 in the next twelve months. Synthetic Biologics&39; stock was trading at . Find the latest Earnings Report Date for Synthetic Biologics, Inc. : Forcasts, revenue, earnings, analysts expectations, ratios for SYNTHETIC BIOLOGICS, INC. Find real-time SYN - Synthetic Biologics Inc stock quotes, company profile, news and forecasts from CNN Business. 295 USD for September 12, Friday with technical analysis.
Although the sellers dominated the stock today, but it showed signs of trend reversal during the latter half, closing Bullish. View which stocks have been most impacted by COVID-19. Description: Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Your gut microbiome contains a large community of microbes, including bacteria, archaea, protists, biologics fungi and viruses. 96%on the last day (Thursday, 10th Dec ) from .
35% during that session. 67% between high and low (Updated on Decem) Sell candidate sincePDF. 2% over the past 2 weeks.
Our comprehensive analysis of fundamental and technical factors gives SYN a rank of 14. Synthetic Biologics Stock Price Forecast, SYN stock price prediction. No earning estimates are available for Synthetic Biologics -- either current or for the upcoming years.
On average, they expect Synthetic Biologics&39; share price to reach . 30% on the last trading day (Friday, 27th Nov ), rising synthetic from . (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced that on Novem, the NYSE American LLC ("NYSE American"), the Company&39;s current listing exchange, notified the Company that it had been granted an extension until to regain compliance. (Heraldkeepers) -- The scope of the report includes a detailed study of global and regional markets. Product Pipeline. Stock Price: SYN (NYSE American) . If a given stock fails to match professional earnings estimates, it usually performs purely.
What this means: InvestorsObserver gives Synthetic Biologics Inc (SYN) an overall rank of 42, which is below average. The estimates are for Synthetic Biologics, Inc. Technical Analysis Summary for Synthetic Biologics Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. · Synthetic Biologics, Inc. (SYN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
A high-level overview of Synthetic Biologics, Inc. 25 and high of . SYN Stock Forecast. NYSEMkt Updated 9:00 PM.
See Synthetic Biologics, Inc. This suggests a possible upside of 271. 28, and an average true range (ATR) of 0.
The price has risen in 5 of the last 10 days and is up by 4. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced that on Novem, the NYSE American LLC ("NYSE American"), the Company&39;s current listing exchange. Common Stock (SYN) at Nasdaq. Join For Free And Start Trading With A Demo Account! · Further, Synthetic Biologics, Inc. Find out now with a free analysis on Synthetic Biologics.
9 Million in Stock Dow Jones Newswires Best Buy Swings to a Loss, Gucci Accuses Guess of Design Knockoffs, synthetic biologics stock forecast Trademark Squatting in China. SYN Stock Forecast - Is SYN a buy or sell? The Synthetic Biologics stock forecast is 1. 6% from the stock&39;s current price. 44%) Wed,, 3:56PM EST Unfortunately, the accuracy of these predictions is not very high, and certainly not a direct buy or sell signal.
-> Tencent stock price us
-> Biggest stock gainers yesterday